Cargando…

Lipodystrophy during pegvisomant therapy: a case report and review of the literature

Detalles Bibliográficos
Autores principales:	Buyuktas, D, Celik, O, Kantarcı, F, Kadioglu, P
Formato:	Texto
Lenguaje:	English
Publicado:	Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2010
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954746/ https://www.ncbi.nlm.nih.gov/pubmed/21049223 http://dx.doi.org/10.1590/S1807-59322010000900018

Ejemplares similares

Insulin lipodystrophy and lipohypertrophy
por: Mokta, Jatinder K., et al.
Publicado: (2013)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

Injection site lipodystrophy and the endocrinologist
por: Gundgurthi, Abhay, et al.
Publicado: (2012)

Membranous lipodystrophy: case report and review of the literature
por: Akpinar, Fatma, et al.
Publicado: (2015)

Giant fibrolipoma mimicking abdominal lipodystrophy
por: Coban, Yusuf Kenan, et al.
Publicado: (2008)

IRF4-Rearranged Large B-Cell Lymphoma on Waldeyer’s Ring: A Case Report
por: Büyüktaş, Deram, et al.
Publicado: (2020)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

A Case of Burkitt’s Lymphoma Mimicking Peritonitis Carcinomatosa
por: Büyüktaş, Deram, et al.
Publicado: (2020)

Nanomedicines in the treatment of acromegaly: focus on pegvisomant
por: Roelfsema, Ferdinand, et al.
Publicado: (2006)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

Localized Lipodystrophy following Single Dose Intramuscular Gentamycin Injection
por: Sharawat, Indar K., et al.
Publicado: (2017)

Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly
por: Kuker, Adriana P, et al.
Publicado: (2021)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Brazilian multicenter study on pegvisomant treatment in acromegaly
por: Boguszewski, Cesar L., et al.
Publicado: (2019)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
por: Giustina, A., et al.
Publicado: (2014)

Iron parameters in patients with partial lipodystrophy and impact of exogenous leptin therapy
por: Akinci, Efe Y, et al.
Publicado: (2021)

Polycystic ovarian syndrome in patients with lipodystrophy: Report of 2 cases with review of literature
por: Pahuja, Isha, et al.
Publicado: (2012)

Safety and Efficacy of Pegvisomant in Pediatric Growth Hormone Excess
por: Tatsi, Christina, et al.
Publicado: (2021)

Left ventricular steal syndrome caused by multiple plexiform coronary artery fistulae: case report, literature review and treatment
por: Biyik, İsmail, et al.
Publicado: (2016)

Commentary on “Gallstone associated celiac trunk thromboembolisms complicated with splenic infarction: A case report’’
por: Tokur, Oguzhan, et al.
Publicado: (2022)

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
por: Strasburger, Christian J, et al.
Publicado: (2018)

Novel subtype of congenital partial lipodystrophy with mandibular hypoplasia, sensorineural deafness and short stature of unknown genetic origin
por: Sasaki, Haruka, et al.
Publicado: (2017)

Tesamorelin: A hope for ART-induced lipodystrophy
por: Patel, Akash, et al.
Publicado: (2011)

Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy
por: Brue, Thierry, et al.
Publicado: (2018)

Pegvisomant in acromegaly: a multicenter real-life study in Argentina
por: Basavilbaso, Natalia Ximena Garcia, et al.
Publicado: (2019)

Pregnancy on tamoxifen: Case-report and review of literature
por: Jyoti, Bajpai, et al.
Publicado: (2016)

Familial Partial Lipodystrophy: A Case Study and Review of Recent Literature
por: Tipu, Ali, et al.
Publicado: (2021)

The renal manifestations of type 4 familial partial lipodystrophy: a case report and review of literature
por: Chen, Ru-Xuan, et al.
Publicado: (2018)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
por: Ma, Lingyun, et al.
Publicado: (2020)

Choroid plexus carcinoma: Case report and review of literature
por: Mishra, Arvind, et al.
Publicado: (2012)

Netherton Syndrome, a Case Report and Review of Literature
por: Boskabadi, Hassan, et al.
Publicado: (2013)

Melanoma in pregnancy: a case report and review of the literature
por: Wielowieyska-Szybińska, Dorota K., et al.
Publicado: (2015)

Conjunctival leiomyosarcoma: A case report and review of literature
por: Al-Mendalawi, Mahmood Dhahir
Publicado: (2017)

Metastasizing Pleomporphic Adenoma - Case reports and review of literature
por: Mani, Suresh, et al.
Publicado: (2019)

Primary Solitary Osseous Hodgkin's Lymphoma: A Case Report and Review of the Literature
por: Geramizadeh, B, et al.
Publicado: (2012)

Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY
por: Grottoli, S., et al.
Publicado: (2022)

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells
por: Cuny, Thomas, et al.
Publicado: (2016)

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
por: Ciresi, A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_egkukk5bvlh50ig5n2per8mt0t